Clinical Trials for Brain Tumor

A Phase I Dose-Escalation Study of Stereotactic Radiosurgery for Brain Metastasis Without Whole Brain Radiation

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with non-hematologic cancers (excluding SCLC, germ cell, or unknown primary) and up to 10 non-brainstem brain mets ≤3 cm, radiation-naïve to the brain, receive single-fraction stereotactic radiosurgery alone with dose escalation to define the maximum tolerated dose. Prior systemic therapy and/or surgery allowed if at least one lesion remains for SRS; outcomes include safety within 90 days and local control/response, without whole-brain radiotherapy.

ClinicalTrials.gov ID: NCT02645487

Phase I/II Trial of Repeat Dosing of Super-Selective Intraarterial Infusion of Erbitux (Cetuximab) and Avastin (Bevacizumab) for Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Pediatric and young adult patients (<22 years) with relapsed/refractory intracranial gliomas (including GBM, anaplastic astrocytoma, oligodendroglioma, and radiographically diagnosed DIPG) receive monthly super-selective intra-arterial cerebral infusions of cetuximab (EGFR inhibitor) plus bevacizumab (VEGF-A inhibitor). Aims to enhance intratumoral delivery and assess safety and preliminary efficacy in measurable/evaluable disease with adequate performance status and organ function.

ClinicalTrials.gov ID: NCT05956821

Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery: A Phase II Study

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with non–small cell solid tumors (excluding SCLC/germ cell) and 1–10 brain metastases receive focal radiation via single-fraction SRS or hypofractionated SBRT (up to 3 fractions), selected by the treating team. The study focuses on neurocognitive outcomes, QoL, and intracranial control over 12 months; excludes leptomeningeal disease, recent brain surgery (<14 days), planned concurrent chemo with radiosurgery, and primary high-grade gliomas.

ClinicalTrials.gov ID: NCT03184038

Phase I/II Trial to Determine the Neurocognitive Decline in Patients With Multiple (>6) Brain Metastases Treated With Distributed Stereotactic Radiosurgery

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with ≥6 brain metastases from solid tumors (including SCLC), no prior whole-brain radiotherapy, and ECOG 0–2/KPS ≥50–60 receive distributed stereotactic radiosurgery to all lesions (largest ≤4 cm) with hippocampal sparing. The study establishes the tolerated SRS dose and then evaluates neurocognitive outcomes (memory) and intracranial control.

ClinicalTrials.gov ID: NCT03508752

UCSD Image-Guided Cognitive-Sparing Radiosurgery for Brain Metastases: Avoidance of Eloquent White Matter and Hippocampal Regions

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with 1–3 brain metastases (≤3 cm; intact or post-resection) receive stereotactic radiosurgery planned with advanced DTI and volumetric MRI to spare eloquent white-matter tracts and bilateral hippocampi, aiming to reduce neurocognitive decline versus historical controls. Excludes prior WBRT, leptomeningeal disease, MRI contraindications, and certain histologies (germ cell, small cell, primary CNS lymphoma).

ClinicalTrials.gov ID: NCT04343157

Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique (ONCO-RT) - A Phase II Trial of Upfront Pulsed Reduced Dose Rate Whole-Brain Radiation Therapy for Brain Metastases

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with solid tumor brain metastases (ECOG 0–1, no prior WBRT, no leptomeningeal disease) receive upfront pulsed reduced dose-rate whole-brain radiation therapy (30 Gy/10 fx) plus memantine to assess feasibility and explore neurocognitive outcomes versus historical WBRT. Prior SRS or resection and prior systemic therapy are allowed with washouts; excludes primary CNS/hematologic malignancies and large (>5 cm) unresected lesions.

ClinicalTrials.gov ID: NCT05045950

Pilot Trial of Spectroscopic MRI-guided, Dose-Escalated Proton Radiation Therapy and Bevacizumab for Recurrent Glioblastoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with recurrent glioblastoma or gliosarcoma after prior standard brain RT (≤63 Gy), ECOG 0–2, single measurable lesion ≤6 cm, receive spectroscopic MRI-guided focal proton re-irradiation (IMPT, 35 Gy/10 fx or 40 Gy/10 fx with SIB) combined with bevacizumab (anti–VEGF-A monoclonal antibody) started before RT. Excludes multifocal disease, prior re-irradiation or bevacizumab, and lesions in regions prone to sMRI artifact.

ClinicalTrials.gov ID: NCT05284643

Surgical Resection of Latent Brain Tumors Prior to Recurrence

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with residual or previously unresected brain tumors after prior chemo/radiation and visible latent disease on imaging undergo clinically indicated pre-recurrence surgical resection, with standard perioperative care and imaging surveillance. Correlative studies include tissue/CSF/blood profiling (including comparison of radiated vs non-radiated tissue and ex vivo sensitivity testing), and outcomes include safety, neurosurgical morbidity, and survival.

ClinicalTrials.gov ID: NCT04810871

A Randomized Trial Evaluating GLIADEL Compared to Stereotactic Radiosurgery in Subjects With Metastatic Brain Disease

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with 1–4 resectable brain metastases (≤4 cm) from solid tumors (RPA I–III, KPS ≥60) are randomized intraoperatively to local chemotherapy with GLIADEL carmustine (BCNU) wafers placed in the resection cavity versus standard postoperative stereotactic radiosurgery to the cavity; remaining lesions (up to three) receive SRS. GLIADEL delivers high local concentrations of the alkylating agent BCNU (DNA crosslinker), and the trial compares local control at 12 months, with neurocognitive and genomic correlatives.

ClinicalTrials.gov ID: NCT04222062

Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with 1–4 resectable brain metastases (≥1 lesion 20–50 mm) from solid tumors (excluding SCLC, lymphoma, germ cell), KPS ≥70, receive neoadjuvant stereotactic radiosurgery to the target lesion followed by gross total resection within 2 weeks; remaining lesions, if any, are treated with SRS. Excludes prior WBRT, brainstem lesions, leptomeningeal disease, and inability to meet optic apparatus dose constraints.

ClinicalTrials.gov ID: NCT01891318